ZEISS Expands Its Portfolio of Eye Care Solutions in Canada to Enhance Patient Treatment and Outcomes
Carl Zeiss Meditec AG, a prominent name in the medical technology field, has made significant strides in enhancing eye care in Canada. The introduction of advanced diagnostic equipment, innovative laser treatment devices, and effective digital workflow tools showcases their commitment to improving patient care. The recent announcement, made on March 24, 2026, emphasizes not just the expansion of their product offerings but also highlights the integration of these advanced solutions into clinical workflows. This enhances the capabilities of eye care professionals across the country.
One of the notable innovations is the CLARUS® 700 equipped with ICGA (Indocyanine Green Angiography) technology. This device allows for simultaneous capture of fluorescein angiography (FA) and indocyanine green (ICG), providing healthcare professionals with detailed imaging necessary for thorough assessments of retinal and glaucoma patients. In addition, it offers a movie mode for all angiography modalities, making clinical evaluations more effective. This year also marks a century of excellence in ZEISS fundus imaging, celebrating its rich history of innovation in ocular imaging dating back to when the first commercially available fundus camera was introduced.
Furthermore, the company has enhanced its retinal therapy capabilities with the VISULAS® green laser, specifically designed for various retinal treatments including diabetic retinopathy. The ergonomic design ensures that while monitoring the parameters, clinicians can maintain focus on their patients, thus providing a more comfortable experience during treatments.
To support efficient clinical workflows, ZEISS has introduced the VISUREF® 600 and VISUCORE 500 refraction devices. The VISUREF 600 consolidates multiple assessments, offering a streamlined workflow that increases diagnostic confidence through comprehensive evaluations. This integration leads to more consistent prescriptions, which is crucial in optimizing patient care. Meanwhile, the VISUCORE 500 combines advanced refraction features into a compact unit, saving valuable clinic space while enhancing overall workflow efficiency.
The enhancements don’t stop at diagnostics and treatment. ZEISS is addressing digital workflow needs with the FORUM® subscription package, which centralizes ophthalmic data management, thereby ensuring a seamless clinical review process. This electronic system minimizes the manual workload by automatically sending patient demographics to instruments and supporting case visualizations, ultimately improving patient care.
The VISULAS yag laser is another pivotal addition to ZEISS’s offerings. This therapeutic tool allows for precise anterior segment photodisruption, enhancing treatment capabilities for ophthalmologists within cataract workflows. Its compact design and intuitive functionality ensure effective patient treatment while also supporting clinician workloads.
Moreover, in the context of healthcare, it's clear that advancements in medical technology play a significant role in improving patient outcomes. While these innovations by ZEISS mark a pivotal moment for eye care in Canada, they also reflect a commitment to ongoing support for eye care professionals. "ZEISS is proud to provide these advanced solutions that will elevate the standard of care in eye health," said Bryan Rossi, President of ZEISS Canada, emphasizing the company's dedication to enriching the quality of life for patients.
The upcoming Ontario Association of Optometrists conference and Canadian Ophthalmological Society conference will serve as platforms where ZEISS’s innovations will be showcased, highlighting their role in shaping the future of eye care technology.
As the field of ophthalmology continues to evolve, tools that improve patient care, increase the efficiency of clinical workflows, and support informed decision-making will be of paramount importance. The advancements made by ZEISS affirm their position as leaders in the medical technology sphere, paving the way for future innovations in eye care.
One of the notable innovations is the CLARUS® 700 equipped with ICGA (Indocyanine Green Angiography) technology. This device allows for simultaneous capture of fluorescein angiography (FA) and indocyanine green (ICG), providing healthcare professionals with detailed imaging necessary for thorough assessments of retinal and glaucoma patients. In addition, it offers a movie mode for all angiography modalities, making clinical evaluations more effective. This year also marks a century of excellence in ZEISS fundus imaging, celebrating its rich history of innovation in ocular imaging dating back to when the first commercially available fundus camera was introduced.
Furthermore, the company has enhanced its retinal therapy capabilities with the VISULAS® green laser, specifically designed for various retinal treatments including diabetic retinopathy. The ergonomic design ensures that while monitoring the parameters, clinicians can maintain focus on their patients, thus providing a more comfortable experience during treatments.
To support efficient clinical workflows, ZEISS has introduced the VISUREF® 600 and VISUCORE 500 refraction devices. The VISUREF 600 consolidates multiple assessments, offering a streamlined workflow that increases diagnostic confidence through comprehensive evaluations. This integration leads to more consistent prescriptions, which is crucial in optimizing patient care. Meanwhile, the VISUCORE 500 combines advanced refraction features into a compact unit, saving valuable clinic space while enhancing overall workflow efficiency.
The enhancements don’t stop at diagnostics and treatment. ZEISS is addressing digital workflow needs with the FORUM® subscription package, which centralizes ophthalmic data management, thereby ensuring a seamless clinical review process. This electronic system minimizes the manual workload by automatically sending patient demographics to instruments and supporting case visualizations, ultimately improving patient care.
The VISULAS yag laser is another pivotal addition to ZEISS’s offerings. This therapeutic tool allows for precise anterior segment photodisruption, enhancing treatment capabilities for ophthalmologists within cataract workflows. Its compact design and intuitive functionality ensure effective patient treatment while also supporting clinician workloads.
Moreover, in the context of healthcare, it's clear that advancements in medical technology play a significant role in improving patient outcomes. While these innovations by ZEISS mark a pivotal moment for eye care in Canada, they also reflect a commitment to ongoing support for eye care professionals. "ZEISS is proud to provide these advanced solutions that will elevate the standard of care in eye health," said Bryan Rossi, President of ZEISS Canada, emphasizing the company's dedication to enriching the quality of life for patients.
The upcoming Ontario Association of Optometrists conference and Canadian Ophthalmological Society conference will serve as platforms where ZEISS’s innovations will be showcased, highlighting their role in shaping the future of eye care technology.
As the field of ophthalmology continues to evolve, tools that improve patient care, increase the efficiency of clinical workflows, and support informed decision-making will be of paramount importance. The advancements made by ZEISS affirm their position as leaders in the medical technology sphere, paving the way for future innovations in eye care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.